|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Furthermore, polymorphisms in the 11β-HSD2 coding gene (HSD11B2) have been linked to high blood pressure and salt sensitivity, major cardiovascular risk factors.
|
28938454 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
A genetic association of a microsatellite flanking the HSD11B2 gene and hypertension in black patients with end-stage renal disease has been reported.
|
10760070 |
2000 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
Recently, we have studied an unusual patient with mild low-renin hypertension and a homozygous mutation in the HSD11B2 gene.
|
9707624 |
1998 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
LHGDN |
The decreased activity of 11beta-HSD2 increases the intracellular availability of cortisol, which might be relevant for the pathogenesis of hypertension and preeclampsia.
|
12911547 |
2003 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
In conclusion, 19-nor-P did not inhibit human 11beta-HSD2 and seems not to be involved in human hypertension.
|
19811365 |
2009 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
The syndrome of apparent mineralocorticoid excess (AME) is an inherited form of human hypertension thought to result from a deficiency of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD).
|
7670488 |
1995 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The syndrome of apparent mineralocorticoid excess (AME) is an inherited form of human hypertension thought to result from a deficiency of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD).
|
7670488 |
1995 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The hypertension phenotype is also epigenetically modulated by HSD11B2 methylation in subjects heterozygous for the mutation.
|
26126204 |
2015 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
HPO |
|
|
|
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters.
|
30239803 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Licorice root, whose active ingredient, glycerrhetinic acid (GA), inhibits renal 11β-HSD2, and thereby causes hypertension in some individuals.
|
28624548 |
2017 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
However, the serum F/E ratio was associated with BP, suggesting a role of 11βHSD2 in mineralocorticoid hypertension.
|
25907225 |
2016 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Our data suggest that HSD11B2 is associated with hypertension in our black subjects with hypertensive end-stage renal disease.
|
8794836 |
1996 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Statistical analyses using the affected sib-pair method did not show significant linkage between the 11beta-HSD2 microsatellite marker and hypertension.
|
9856363 |
1998 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
We have investigated the role of HSD11B2 in hypertension in 377 genetically homogeneous essential hypertensives from North Sardinia.
|
15673310 |
2005 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Our data suggest that kidney-specific deficiency of 11β-HSD2 leads to salt-dependent hypertension, which is attributed to mineralocorticoid receptor-epithelial sodium channel-Na<sup>+</sup>-Cl<sup>-</sup> cotransporter activation in the kidney, and provides evidence that renal dysfunction is essential for developing the phenotype of apparent mineralocorticoid excess.
|
28559392 |
2017 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Because the hypertension associated with AME is of the salt-sensitive type, it seemed possible that decreases in 11-HSD2 activity might be associated with salt sensitivity.
|
10948076 |
2000 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The deactivation of glucocorticoid by 11βHSD2 controls ligand access to glucocorticoid and mineralocorticoid receptors: loss of function promotes salt retention and hypertension.
|
29138984 |
2017 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
RGD |
In the development of diabetes-induced hypertension, the effect of spironolactone on mean systolic blood pressure may be associated with the mineralocorticoid effects of corticosterone on renal MR, as well as an alteration of renal 11beta-HSD2 activity and its mRNA expression in insulin-dependent diabetic rats.
|
10792625 |
2000 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Serum F/E ratio and cortisone allow to identify partial 11βHSD2 deficiencies, as occurs in heterozygous subjects, who would be susceptible to develop arterial hypertension.
|
29617893 |
2018 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
11 beta-HSD2 activity is not decreased in glucocorticoid hypertension (Cushing's syndrome).
|
9683905 |
1998 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure.
|
11082157 |
2000 |
|
Hypertensive disease
|
0.700 |
PosttranslationalModification
|
group |
LHGDN |
These results show a clear link between the epigenetic regulation through repression of HSD11B2 in PBMC DNA and hypertension.
|
18178212 |
2008 |
|
Hypertensive disease
|
0.700 |
PosttranslationalModification
|
group |
BEFREE |
These results show a clear link between the epigenetic regulation through repression of HSD11B2 in PBMC DNA and hypertension.
|
18178212 |
2008 |
|
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Furthermore, in the rat, an association between placental 11 beta HSD activity and the subsequent development of hypertension in the offspring has been reported.
|
7883847 |
1995 |